Lara G, Cuadrado-Gamarra J I, de Pedro-Cuesta J, Esteban E M, Giménez-Roldán S, Luis-González S
National Institute of Neurology and Neurosurgery, Havana, Cuba.
Pharmacoepidemiol Drug Saf. 2006 Jul;15(7):521-6. doi: 10.1002/pds.1150.
The purpose of this study is to describe and evaluate the use of levodopa in Cuba in order to provide a basis for intervention aimed at improving pharmacological treatment of individuals presenting with Parkinson's disease (PD).
We studied the amount of levodopa, both plain and combined, distributed by the central laboratory to hospital and community pharmacies in Cuba in the period 1993-1998. An internationally established drug-classification system and a reported method for epidemiological assessment of levodopa sales were applied. Sweden in 1994 served as the reference population.
National crude rates of levodopa use basically remained stable since 1994, and in 1998 stood at 0.11 defined daily dose (DDD) per 1000 inhabitants/day, approximately 15 times lower than the corresponding figure for the reference population. Annual provincial use of levodopa showed considerable geographical variation, with the lowest rates in the eastern provinces and the highest rates in Havana City (Ciudad de La Habana). Adjustment for age reduced such differences by approximately 50%.
Levodopa use in Cuba is low and consistent with the reported low prevalence of the diagnosis of PD. Results suggest that the diagnosis and treatment of PD can be improved, with emphasis on better detection of PD.
本研究旨在描述和评估古巴左旋多巴的使用情况，以便为旨在改善帕金森病（PD）患者药物治疗的干预措施提供依据。
我们研究了1993 - 1998年期间中央实验室向古巴医院和社区药房分发的普通和复方左旋多巴的数量。应用了国际上既定的药物分类系统和一种报告的左旋多巴销售流行病学评估方法。1994年的瑞典作为参考人群。
自1994年以来，全国左旋多巴使用的粗率基本保持稳定，1998年为每1000居民/天0.11限定日剂量（DDD），约为参考人群相应数字的15分之一。左旋多巴的省级年度使用情况显示出相当大的地理差异，东部省份使用率最低，哈瓦那市（Ciudad de La Habana）使用率最高。年龄调整使这种差异减少了约50%。
古巴左旋多巴的使用量较低，与报道的帕金森病低患病率相符。结果表明，帕金森病的诊断和治疗可以得到改善，重点是更好地检测帕金森病。
